Results 11 to 20 of about 7,946 (150)

Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial. [PDF]

Addiction
Abstract Background and aims By assessing neuroaffective response to motivationally relevant cues before a quit attempt, we have shown that smokers who attribute greater incentive salience to cigarette‐related cues than non‐cigarette‐related rewards (Sign‐trackers, ST) benefit more from varenicline compared with smokers with the opposite neuroaffective
Versace F, Green CE, Cui Y, Robinson JD, Deweese MM, Minnix JA, Kypriotakis G, Kim S, Karam-Hage M, Cinciripini PM.   +9 more
europepmc   +2 more sources

Effectiveness of Alcohol Use Disorder Pharmacotherapies by Sex: Systematic Review and Meta-Analysis. [PDF]

Drug Alcohol Rev
ABSTRACT Issues Alcohol use disorder (AUD) shows sex‐related differences in prevalence, harm and treatment response. Despite growing interest in sex differences, evidence synthesis evaluating pharmacotherapy effectiveness by sex remains limited. Approach Web of Science, PubMed, Scopus, PsycINFO and Cochrane were searched twice.
Allen J, Jones A, Shorter GW, Montgomery C, Kougiali Z, Bagnall A, Adshead C, Smith J, Burton S, Atkinson A, Guelen L, Rose A.   +11 more
europepmc   +2 more sources

Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting

BMJ Open, 2021
Objectives To evaluate the real-world association between varenicline and neuropsychiatric adverse events (NPAEs) in general and chronic obstructive pulmonary disease (COPD) population with and without psychiatric disorders compared with nicotine ...
Yuanyuan Wang, Bob Wilffert, Eelko Hak, H. Marike Boezen, Jens H. Bos, Catharina C.M. Schuiling-Veninga, Job F. M. van Boven   +6 more
doaj   +1 more source

The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence

Addictive Behaviors Reports, 2018
Introduction: The degree to which smokers quit successfully with varenicline is strongly associated with their adherence to the medication regimen. Thus, measuring varenicline adherence to identify smokers needing additional intervention is a priority ...
Grace Crawford, Nancy Jao, Annie R. Peng, Frank Leone, Ravi Kalhan, Rachel F. Tyndale, Jessica Weisbrot, Brian Hitsman, Robert Schnoll   +8 more
doaj   +1 more source

A case report on varenicline induced delirium in an alcohol and nicotine dependent patient

Indian Journal of Psychological Medicine, 2015
Varenicline is a smoking cessation agent. Varenicline acts as a partial agonist of α4β2 neuronal nicotinic acetylcholine receptor and prevents nicotine binding to the same.
A Lakshmi Narayan, H S Virupaksha, G Thejaswi, G R Saraswathy, V Madhavan, Murali Thyloth   +5 more
doaj   +1 more source

Varenicline and Risk of Self-Harm: A Nested Case-Control Study. [PDF]

PLoS ONE, 2016
BACKGROUND:Smoking remains a serious public health concern. Pharmacotherapy for smoking cessation, including bupropion and varenicline, are proven means to increase quit rates.
Mina Tadrous, Diana Martins, Zhan Yao, Muhammad M Mamdani, David N Juurlink, Tara Gomes, Tony Antoniou   +6 more
doaj   +1 more source

Use of varenicline and nicotine replacement therapy in people with and without general practitioner-recorded dementia: retrospective cohort study of routine electronic medical records

BMJ Open, 2019
Objectives Our primary objective was to estimate smoking prevalence and prescribing rates of varenicline and nicotine replacement therapy (NRT) in people with and without general practitioner (GP)-recorded dementia.
Amy Taylor, Tim Jones, Taha Itani, Richard Martin, Gemma Taylor, Kyla Thomas, Neil Davies   +6 more
doaj   +1 more source

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. [PDF]

PLoS ONE, 2016
UNLABELLED:Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains.
Robert C Smith, Revital Amiaz, Tian-Mei Si, Lawrence Maayan, Hua Jin, Sylvia Boules, Henry Sershen, Chunbo Li, Juanjuan Ren, Yanhong Liu, Mary Youseff, Abel Lajtha, Alessandro Guidotti, Mark Weiser, John M Davis   +14 more
doaj   +1 more source

Adverse Neuropsychiatric Events Associated with Varenicline: A Case Series

Psychiatry and Behavioral Sciences, 2021
Varenicline is an orally administered α4β2 nicotinic acetylcholine (Ach) receptor, partial agonist. This drug has been known to be more effective in the treatment of nicotine withdrawal than bupropion and nicotine replacement therapies ...
Burak Erman Menku, Taylan Altiparmak, Bahadir Genis, Behcet Cosar   +3 more
doaj   +1 more source

Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase

Journal of Pharmacological Sciences, 2018
Smoking cessation is the most effective treatment in patients with emphysema and lung inflammation. The aim of the present study was to examine the effect of varenicline, a smoking cessation drug, on emphysema in porcine pancreatic elastase (PPE)-inhaled
Mitsuhisa Koga, Yuki Kanaoka, Tetsushi Tashiro, Nagisa Hashidume, Yasufumi Kataoka, Atsushi Yamauchi   +5 more
doaj   +1 more source